Condensed Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenue	$ 83,417	$ 67,251	$ 52,441
Cost of good sold	18,746	15,030	13,181
Gross profit	64,671	52,221	39,260
Operating expenses:
Research and development	16,738	8,997	4,454
Clinical and regulatory affairs	4,439	2,169	2,115
Marketing and sales	44,655	31,869	26,483
General and administrative	15,525	13,410	8,550
Distribution contract termination	1,730	0	0
Total operating costs and expenses	83,087	56,445	41,602
Loss from operations	(18,416)	(4,224)	(2,342)
Other income (expense):
Interest income	23	30	48
Interest expense	(32)	(16)	(192)
Gain on sale of equipment	141	0	0
Other income(expense), net	(32)	(174)	73
Change in fair value of contingent consideration related to acquisition (Note 10)	(10,500)	0	0
Total other expense	(10,400)	(160)	(71)
Net loss before income tax	(28,816)	(4,384)	(2,413)
Income tax benefit	86	15,037	(21)
Net earnings (loss)	$ (28,730)	$ 10,653	$ (2,434)
Basic net earnings (loss) per share	$ (0.51)	$ 0.22	$ (0.05)
Diluted net earnings (loss) per share	$ (0.51)	$ 0.21	$ (0.05)
Shares used in computing basic net (earnings) loss per share	56,592	48,902	45,194
Shares used in computing diluted net earnings (loss) per share	56,592	50,544	45,194